Latest Issue
GLP-1 & Metabolic Watch · Vol. 1 Issue 3
The Access Gap Widens
31 May – 4 July 2026 · 21 High-Signal Items across six domains
● Published 4 July 2026
The gap between demand and safe, subsidised supply widens — and turns dangerous. Wegovy's PBS listing for cardiovascular disease with obesity still hasn't landed, and Lilly says the Mounjaro door is shut. Into that vacuum, the grey market becomes a public-health story: Victoria reports liver-toxicity cases from unapproved "retatrutide" as the TGA mounts its strongest peptide crackdown. Meanwhile the science leaps ahead — retatrutide posts bariatric-level Phase 3 data at ADA — and Canada becomes the first G7 country with generic semaglutide.
Issue Highlights
- Wegovy PBS listing for eCVD + obesity still not commenced
- Victoria: 6 liver-toxicity cases from grey-market "retatrutide"
- TGA's strongest-ever peptide crackdown; $2M seizure
- Canada = first G7 generic semaglutide (~⅓ brand price)
- Retatrutide TRIUMPH-1: 28.3% weight loss at ADA 2026
- GLP-1 companion nutrition & muscle preservation go structural
Read Issue 3 →
4 July 2026 · 21 signals · Six domains
Coverage Domains